AI could spot breast cancer risk better than current methods

NCT ID NCT05968157

Recruiting now Diagnosis Sponsor: University of Massachusetts, Worcester Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether an artificial intelligence program called Mirai can better identify women at high risk for breast cancer compared to traditional risk models. Researchers will invite 200 women flagged as high-risk by Mirai to receive an additional breast MRI. The goal is to see if the AI-guided approach finds more cancers early, especially across different racial and ethnic groups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Artificial intelligence software (Mirai) and breast MRI
What this could lead to: If successful, this could show that AI-based risk assessment is more accurate than current methods, leading to earlier breast cancer detection and more personalized screening.
What could go wrong: This is a relatively small, early-stage study (200 participants) comparing two screening approaches, not a treatment trial. The AI may not prove better in practice, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

UMass Medical School
RECRUITING

Worcester, Massachusetts, 01655, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.